Word renown scientists pioneering a new generation of immune-modulating therapeutics designed to restore immune balance rather than suppress it.
TRegRX has developed a novel fusion protein and antibody-drug conjugate (ADC) platform repairs defective IL-2 receptor (IL-2R) signaling in Tregs, restoring immune balance without broad immunosuppression.
TRegRX is advancing its PDC-NAEi and potential ADC platform toward preclinical IND-enabling studies with the goal of entering first-in-human trials in type 1 diabetes, multiple sclerosis, and systemic lupus erythematosus, followed by additional programs in rheumatoid arthritis, inflammatory bowel disease and severe asthma.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.